Theravance Biopharma Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the three months ended March 31, 2024, none of our Section 16 officers or directors adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below:
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Rule 10b5-1 | | |
| | | | | | | Duration of Trading | | Trading Arrangement? | Number of Ordinary | |
| Name and Title | Action | Date | Arrangement | (Y / N) (1) | Shares to be Sold | |||||
| Rhonda F. Farnum,Chief Business Officer and Senior Vice President, Commercial & Medical Affairs | | Adoption | | March 14, 2024 | | June 24, 2024 - July 30, 2025 | | Y | | Up to 90,000 |
| (1) | Denotes whether the trading plan is intended to satisfy the affirmative defense Rule 10b5-1(c) of the Exchange Act. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.